Drug intelligence / Profile preview

anti-CD19 CAR-transduced T cells

Development stage: Unknown
Lead developer: Shenzhen Inno Immune
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

anti-CD19 CAR-transduced T cells (also known as yinnuokati-19) is an autologous chimeric antigen receptor T-cell (CAR-T) therapy developed by Shenzhen Innovation Immunotechnology. It consists of patient-derived T cells genetically engineered to express a CAR targeting the B-lymphocyte antigen CD19. Upon administration, these CAR-T cells specifically bind to CD19-expressing B cells, triggering T-cell activation, expansion, and the targeted elimination of malignant B cells. The therapy is being evaluated in Phase 1/2 clinical trials in China for the treatment of CD19-positive B-cell malignancies, including B-cell leukemia and B-cell lymphoma.

Other names: anti-CD19 CAR-T cell therapyanti-CD-19 CAR-T cell therapyanti-CD 19 CAR-T cell therapyanti-CD19 CAR-T cellsanti-CD-19 CAR-T cellsanti-CD 19 CAR-T cellsyinnuokati-19yinnuokati19yinnuokati 19yinnuokati-19 cell injectionyinnuokati19 cell injectionyinnuokati 19 cell injection因诺卡替-19因诺卡替-19细胞注射液

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on anti-CD19 CAR-transduced T cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-CD19 CAR-transduced T cells.

Explore the full profile